Macrophages: Targets for next-generation cancer immunotherapy
Cancer Cell · 2026-03 · 44 (3) · 498-518
DOI: 10.1016/j.ccell.2026.01.020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-03. Verfasst von Xiaoqi Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Marc and Jennifer Lipschultz Precision Immunology Institute, Ic…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Tumor-Associated Macrophages, Macrophages. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Tumor-associated macrophages (TAM) are among the most abundant immune cells in tumors and exhibit striking functional plasticity, enabling them to either promote tumor progression or mediate malignant cell elimination. This paradox arises from TAM heterogeneity shaped by diverse developmental origins, transcriptional programs, and microenvironmental cues. Here, we review next-generation strategies to therapeutically target TAMs, with dual goals of relieving macrophage-driven immunosuppression and unleashing their tumoricidal potential. These approaches include effectorization by modulating "eat-me" pathways and targeted activation, as well as reprogramming TAMs through inhibiting immune checkpoints, rewiring signaling, epigenetics, and metabolism, and targeting myeloid progenitors at sites of hematopoiesis. We also discuss advances in bioengineering, including bispecific antibodies, masked cytokines, genetic engineering, targeted lipid nanoparticles and anti-TAM CAR T cells, that enable increasingly precise control of macrophage biology. These therapies have transformative potential to enhance tumor-specific T cells, and provide an independent alternative arm of immunity, to enable durable cancer eradication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department o…
- Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Immunology & Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, U…
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Institutes of Health
- Applebaum Foundation
- Melanoma Research Alliance
Zitieren
APA
Sun, X., Park, M. D., Merad, M., & Brown, B. D. (2026). Macrophages: Targets for next-generation cancer immunotherapy. Cancer Cell, 44(3), 498-518. https://doi.org/10.1016/j.ccell.2026.01.020
Vancouver
Sun X, Park MD, Merad M, Brown BD. Macrophages: Targets for next-generation cancer immunotherapy. Cancer Cell. 2026;44(3):498-518. doi:10.1016/j.ccell.2026.01.020
BibTeX
@article{Sun2026,
author = {Sun, Xiaoqi and Park, Matthew D and Merad, Miriam and Brown, Brian D},
title = {Macrophages: Targets for next-generation cancer immunotherapy},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {3},
pages = {498--518},
doi = {10.1016/j.ccell.2026.01.020}
}
EUVIMED